Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET.
馬薩諸塞州劍橋，2024年11月22日（環球資訊網）—— Seres therapeutics公司（納斯達克：MCRB），一家領先的現場生物治療公司，今天宣佈首席執行官埃裏克·沙夫將於2024年12月3日下午4:30參加派傑投資第36屆年度醫療健康大會的爐邊談話。
A live webcast of the chat will be accessible through the "Events and Presentations" tab on the "Investors and News" section of the Company's website at and will be available for replay following the event.
此次聊天的直播網絡廣播將通過公司網站「投資者與資訊」部分的「活動與演示」標籤訪問，並將在活動結束後提供重播。
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome therapeutic, and which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit .
投資者和媒體聯繫人：IR@serestherapeutics.com，卡羅·坦齊博士，肯達爾投資者關係公司，ctanzi@kendallir.com，Seres Therapeutics，Inc。
seres therapeutics公司（納斯達克股票代碼：MCRB）是一家臨床階段的公司，專注於通過新穎的活性生物治療產品，改善在醫療易受傷害人群中患者的治療結果。Seres領導了VOWSt的成功開發和批准，這是首個FDA批准的口服菌群治療產品，並於2024年9月被售予雀巢健康科學公司。公司正在開發SER-155，該產品在臨床研究中顯示了對進行異基因造血幹細胞移植（allo-HSCT）的患者血流感染和相關併發症的顯著減少（與安慰劑相比）。SER-155及公司的其他正在研發中的項目旨在針對多種與疾病相關的途徑，這些產品是通過對標準的克隆細胞銀行進行培養製備的，而非像VOWSt那樣採用供體生產工藝。除了allo-HSCt之外，公司還打算評估SER-155及其他培養的活性生物治療產品候選者在其他醫療易受傷害患者群體中的應用，包括自體-HSCt患者、中性粒細胞減少症的癌症患者、CAR-T細胞接受者、慢性肝病患者、固體器官移植接受者，以及重症監護單位和長期急性護理設施的患者。更多信息，請訪問。
Investor and Media Contacts:
IR@serestherapeutics.com
投資者和媒體聯繫方式：IR@serestherapeutics.com，卡羅·坦齊博士，肯達爾投資者關係公司，ctanzi@kendallir.com，Seres Therapeutics，Inc。
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
肯達爾投資者關係公司
ctanzi@kendallir.com
ctanzi@kendallir.com
This press release was published by a CLEAR Verified individual.
此新聞發佈是由經過驗證的個人發佈的。
Source: Seres Therapeutics, Inc.
資料來源：Seres Therapeutics, Inc.
